CRESCENT BIOPHARMA, INC. Prepaid Expense and Other Assets, Current
CRESCENT BIOPHARMA, INC. (CBIO) had Prepaid Expense and Other Assets, Current of $7.41 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes
us-gaap:PrepaidExpenseAndOtherAssetsCurrent · last filed 2026-07-30
- 2026-06-30: Prepaid Expense and Other Assets, Current $7.41M.
- 2026-03-31: Prepaid Expense and Other Assets, Current $6.40M.
- 2025-12-31: Prepaid Expense and Other Assets, Current $5.46M.
- 2025-09-30: Prepaid Expense and Other Assets, Current $1.30M.
| Period end | Prepaid Expense and Other Assets, Current | Prepaid Expense and Other Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $7.41M 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $6.40M 10-Q · filed 2026-04-29 | |
| 2025-12-31 | $5.46M 10-Q · filed 2026-07-30 | |
| 2025-09-30 | $1.30M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $1.58M 10-Q · filed 2025-07-31 | |
| 2025-03-31 | $377.99K 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $38.00K 10-K · filed 2026-02-26 | $371.28K 10-K · filed 2025-02-13 |
| 2024-09-30 | $1.25M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $1.47M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $1.99M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $2.00M 10-K · filed 2025-02-13 | |
| 2023-09-30 | $2.60M 10-Q · filed 2023-11-03 | |
| 2023-06-30 | $2.33M 10-Q · filed 2023-08-02 | |
| 2023-03-31 | $3.08M 10-Q · filed 2023-05-03 | |
| 2022-12-31 | $2.84M 10-K · filed 2024-03-27 | |
| 2022-09-30 | $2.22M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $1.02M 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $947.39K 10-Q · filed 2022-04-28 | |
| 2021-12-31 | $533.80K 10-K · filed 2023-03-29 | |
| 2021-09-30 | $2.21M 10-Q · filed 2021-11-02 | |
| 2021-06-30 | $1.46M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $1.24M 10-Q · filed 2021-05-03 | |
| 2020-12-31 | $1.24M 10-K · filed 2022-03-03 | |
| 2020-09-30 | $2.77M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $3.51M 10-Q · filed 2020-07-31 | |
| 2020-03-31 | $2.06M 10-Q · filed 2020-05-01 | |
| 2019-12-31 | $4.33M 10-K · filed 2021-03-02 | |
| 2019-09-30 | $3.91M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $2.30M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $2.83M 10-Q · filed 2019-05-02 | |
| 2018-12-31 | $2.35M 10-K · filed 2020-02-28 | |
| 2018-09-30 | $2.61M 10-Q · filed 2018-11-02 | |
| 2018-06-30 | $3.48M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $3.48M 10-Q · filed 2018-05-03 | |
| 2017-12-31 | $3.29M 10-K · filed 2019-03-06 | |
| 2017-09-30 | $1.02M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $502.15K 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $697.06K 10-Q · filed 2017-05-08 | |
| 2016-12-31 | $478.50K 10-K · filed 2018-03-06 | |
| 2016-09-30 | $1.24M 10-Q · filed 2016-11-04 | |
| 2016-06-30 | $1.45M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $683.37K 10-Q · filed 2016-05-04 | |
| 2015-12-31 | $441.81K 10-K · filed 2017-03-01 | |
| 2015-09-30 | $718.23K 10-Q · filed 2015-11-12 | |
| 2015-06-30 | $534.85K 10-Q · filed 2015-08-06 | |
| 2015-03-31 | $777.08K 10-Q · filed 2015-05-05 | |
| 2014-12-31 | $916.25K 10-K · filed 2016-02-29 | |
| 2014-09-30 | $587.82K 10-Q · filed 2014-10-31 | |
| 2014-06-30 | $881.71K 10-Q · filed 2014-07-31 | |
| 2014-03-31 | $719.02K 10-Q · filed 2014-05-09 | |
| 2013-12-31 | $2.57M 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |